New choices for patient needing kidney transplantation across antibody barriers

Journal of Renal Care

Volumn 34, Issue 2, 2008, Pages 85-93

  Higgins, Robert ^a,d   Hathaway, Mark ^b   Lowe, David ^b   Zehnder, Daniel ^a,c   Krishna, Nithya ^a   Hamer, Rizwan ^a,c   Briggs, David ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

Author keywords

ABO antibody; Antibody incompatible transplantation; HLA antibody; Kidney tranplant; Plasma exchange; Plasmapheresis

Indexed keywords

HLA ANTIGEN;

BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CLINICAL PROTOCOL; DECISION MAKING; DONOR SELECTION; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE DELIVERY; HEALTH SERVICE; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVING DONOR; METHODOLOGY; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PLASMAPHERESIS; REVIEW; RISK FACTOR; STATISTICS; TRANSPLANTATION; TREATMENT OUTCOME; UNITED KINGDOM;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; CHOICE BEHAVIOR; CLINICAL PROTOCOLS; DONOR SELECTION; GRAFT REJECTION; GRAFT SURVIVAL; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION; PLASMAPHERESIS; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 44949175817     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2008.00025.x     Document Type: Article

References (33)

1. British Transplantation Society Standards document. (2006). Antibody Incompatible Transplantation. http://www.bts.org.uk (accessed 1 October 2006).
2. Cardella C.J., Sutton D., Uldall P.R. et al. (1977). Intensive plasma exchange and renal transplant rejection. Lancet 1(8005), 264.
3. Carlisle J. & Swart M. (2007). Mid-term survival after abdominal aortic aneurysm surgery predicted by cardiopulmonary exercise testing. British Journal of Surgery 94, 966-969.
4. de Klerk M., Witvliet M.D., Haase-Kromwijk B.J. et al. (2006). A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation 82, 1616-1620.
5. Gentry S.E., Segev D.L., Simmerling M. et al. (2007). Expanding kidney paired donation through participation by compatible pairs. American Journal of Transplantation 7(10): 2361-2370.
6. Gloor J.M., DeGoey S., Ploeger N. et al. (2004). Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 78, 221-227.
7. Gloor J. (2005). Kidney transplantation in the hyperimmunized patient. Kidney International 146, 11-21.
8. Glotz D., Antoine C., Julia P. et al. (2002). Desensitisation and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). American Journal of Transplantation 2, 758-760.
9. Haas M., Rahman M.H., Racusen L.C. et al. (2006). C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. American Journal of Transplantation 6, 1829-1840.
10. Heinemann F.M., Roth I., Rebmann V. et al. (2007). Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Human Immunology 68(6), 500-506.
11. Higgins R., Hathaway M., Lowe D. et al. (2007). Blood levels of donor-specific HLA antibodies after renal transplantation; resolution of rejection in the presence of circulating donor specific antibody. Transplantation 84(7), 876-884.
12. Higgins R.M., Bevan D.J., Carey B.S. et al. (1996). Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 348, 1208-1211.
13. Higgins R.M., Bevan D.J., Vaughan R.W. et al. (1996). Five year follow up of patients successfully transplanted after immunoadsorption to remove anti-HLA antibodies. Nephron 74, 53-57.
14. Higgins R.M. & Bevan D.J. (1995). Antibody removal therapy in transplantation. Transplantation Reviews 9, 177-199.
15. Ishida H., Miyamoto N., Shirakawa H. et al. (2007). Evaluation of immunosuppressive regimens in ABO-Incompatible living kidney transplantation-single center analysis. American Journal of Transplantation 7, 825-831.
16. Jordan S.C., Tyan D., Stablein D. et al. (2004). Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. Journal of American Society of Nephrology 15(12), 3256-3262.
17. Locke J.E., Zachary A.A., Haas M. et al. (2007). The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. American Journal of Transplantation 7(4), 842-846.
18. Montgomery R.A., Zachary A.A., Ratner L.E. et al. (2005). Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 294, 1655-1663.
19. Montgomery R.A., Zachary A.A., Racusen L.C. et al. (2000). Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70, 887-895.
20. Nordén G., Briggs D., Cockwell P. et al. (2006). ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation 13(2), 148-153.
21. Palmer A., Taube D., Welsh K. et al. (1989). Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1(8628), 10-12.
22. Pei R., Lee J., Chen T. et al. (1999). Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Human Immunology 60, 1293-1302.
23. Rydberg L., Bengtsson A., Samuelsson O. et al. (2005). In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transplantation International 17(11), 666-672.
24. Segev D.L., Simpkins C.E., Warren D.S. et al. (2006). Continued success with high-titer ABO-incompatible transplantation without anti-CD20 or splenectomy. Abstract, World Transplant Congress, Boston.
25. Soulillou J.P., Guyot C., Guimbretiere J. et al. (1983). Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 35, 158-162.
26. Stegall M.D., Gloor J., Winters J.L. et al. (2006). A comparison of plasmapheresis versus high-dose IVIG desensitisation in renal allograft recipients with high levels of donor specific alloantibody. American Journal of Transplantation 6, 346-351.
27. Sumitran-Karuppan S. (1999). The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies. Transplantation 68, 502-509.
28. Takahashi K., Saito K., Takahara S. et al. (2004). Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. American Journal of Transplantation 4, 1089-1096.
29. Taube D.H., Williams D.G., Cameron J.S. et al. (1984). Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1(8381), 824-828.
30. Tydén G., Donauer J., Wadström J. et al. (2007). Implementation of a protocol for ABO-incompatible kidney transplantation(ndash)a three-center experience with 60 consecutive transplantations. Transplantation 83(9), 1153-1155.
31. Vo A.A., Wechsler E.A., Wang J. et al. (2007). Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitised patients desensitised with IVIg and rituximab. American Journal of Transplantation 7, 1-6.
32. Williams G.M., Hume D.M., Hudson R.P. Jr. et al.(1968). 'Hyperacute' renal-homograft rejection in man. New England Journal of Medicine 279, 611-618.
33. Zachary A.A., Montgomery R.A., Jordan S.C. et al. (2007). 14th International HLA and immunogenetics workshop: report on understanding antibodies in transplantation. Tissue Antigens 69(Suppl 1), 160-173.